6/28/23, 12:05 AM ALBIOS Pathway Feedback Search Clinical Topics Home Studies ALBIOS ALBIOS Disease Sepsis and septic shock Trial question What is the role of albumin replacement in patients with severe sepsis or septic shock? Study design Multi-center Open label RCT Population Characteristics of study participants 39.4% female N = 1818 60.6% male 1818 patients (717 female, 1093 male) Inclusion criteria: patients with severe sepsis Key exclusion criteria: age < 18 years, terminal state, known adverse reaction to albumin administration, severe sepsis or septic shock in patients after proved or suspected head injury, congestive HF (NYHA class of 3 or 4), hepatic cirrhosis with ascites, intestinal malabsorption syndrome, nephrotic syndrome, burns Interventions N=903 albumin (20% albumin and crystalloid solution for fluid replacement) N=907 crystalloids (crystalloid solution alone for fluid replacement) Primary outcome https://web.pathway.md/studies/recDDWvjWNTP2rY2G 1/2 6/28/23, 12:05 AM ALBIOS Pathway Death at 28 days 32.0 % 32 31.8 24.0 % 16.0 % 8.0 % No significant difference 0.0 % Albumin Crystalloids No significant difference in death at 28 days (31.8% vs. 32%; RR 1, 95% CI 0.87 to 1.14) Secondary outcomes No significant difference in death from any cause at 90 days (41.1% vs. 43.6%; RR 0.94, 95% CI 0.85 to 1.05) Conclusion In patients with severe sepsis, albumin was not superior to crystalloids with respect to death at 28 days. Reference Caironi P, Tognoni G, Masson S et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 2014 Apr 10;370(15):1412-21. Open reference URL https://web.pathway.md/studies/recDDWvjWNTP2rY2G 2/2